A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota

Mol Nutr Food Res. 2017 Aug;61(8). doi: 10.1002/mnfr.201600622. Epub 2017 Jun 8.

Abstract

We investigated the effect of a high fructose diet (HFD) on Sprague Dawley rats and the impact of a synbiotic composed of Lactobacillus fermentum CECT5716 and fructooligosaccharides. Feeding the HFD for 5 weeks resulted in liver steatosis and insulin resistance but not obesity. These changes were associated with increased production of short-chain fatty acids and increased Bacteroidetes in feces, with an augmented Bacteroidetes/Firmicutes ratio, among other changes in the microbiota. In addition, barrier function was weakened, with increased LPS plasma levels. These data are consistent with increased fructose availability in the distal gut due to saturation of absorptive mechanisms, leading to dysbiosis, endotoxemia, hepatic steatosis, and insulin resistance. Treatment with the synbiotic prevented some of the pathological effects, so that treated rats did not develop steatosis or systemic inflammation, while dysbiosis and barrier function were greatly ameliorated. In addition, the synbiotic had hypolipidemic effects. The synbiotic composed by L. fermentum CECT5716 and fructooligosaccharides has beneficial effects in a model of metabolic syndrome induced by a HFD, suggesting it might be clinically useful in this type of condition, particularly considering that high fructose intake has been related to metabolic syndrome in humans.

Keywords: Barrier function; Fructose; Leptin; Metabolic syndrome; Microbiota.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diet
  • Disease Models, Animal
  • Fatty Acid-Binding Proteins / metabolism
  • Fatty Acids, Volatile / metabolism
  • Fructose / adverse effects
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / physiology
  • Insulin Resistance
  • Limosilactobacillus fermentum*
  • Male
  • Metabolic Syndrome / diet therapy
  • Metabolic Syndrome / etiology
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / prevention & control*
  • Oligosaccharides / pharmacology*
  • Rats, Sprague-Dawley
  • Receptors, Adiponectin / metabolism
  • Synbiotics*

Substances

  • Fabp1 protein, rat
  • Fatty Acid-Binding Proteins
  • Fatty Acids, Volatile
  • Oligosaccharides
  • Receptors, Adiponectin
  • adiponectin receptor 1, rat
  • fructooligosaccharide
  • Fructose